Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 8:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 701 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: PVD Clear all
Completed Phase 2 Interventional

Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia

NCT00060892
View directory record Official record
Conditions
Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia
Interventions
HGF plasmid
Genetic
Lead sponsor
AnGes USA, Inc.
Industry
Eligibility
40 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2008 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Not applicable Interventional Results available

The Complete® SE SFA Study for the Treatment of SFA/PPA Lesions

NCT00814970
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Complete SE Vascular Stent System
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
4
States / cities
Fremont, California • Gainesville, Florida • Ocala, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Jun 25, 2026, 8:07 PM EDT
Recruiting Not applicable Interventional

AcoArt Litos PCB Below-the-knee Global Trial

NCT06330493
View directory record Official record
Conditions
Chronic Limb-Threatening Ischemia
Interventions
PCB, PTA
Device
Lead sponsor
Acotec Scientific Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
17
States / cities
Concord, California • Fremont, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 25, 2026, 8:07 PM EDT
Not listed Phase 1 Interventional

Autologous CD34+ Stem Cell Injection for Severe Intermittent Claudication (Leg Pain)

NCT00311805
View directory record Official record
Conditions
Peripheral Artery Disease, Severe Intermittent Claudication
Interventions
Autologous Stem Cells (CD34+)
Biological
Lead sponsor
Losordo, Douglas, M.D.
Individual
Eligibility
21 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Birmingham, Alabama • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Not applicable Interventional

Implementation of ABI and WIfI in Rural Health Clinics

NCT04337723
View directory record Official record
Conditions
Peripheral Arterial Disease, Diabetic Foot, Diabetes Mellitus
Interventions
ABI/WIFI scoring
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Jun 25, 2026, 8:07 PM EDT
Recruiting Not applicable Interventional

EVERO Drug-coated Balloon (DCB) Randomized Trial

NCT07144150
View directory record Official record
Conditions
Peripheral Vascular Disease, Peripheral Arterial Disease
Interventions
Evero DCB, Paclitaxel DCB
Combination Product
Lead sponsor
Cook Research Incorporated
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Gainesville, Florida • Jacksonville, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Creatine Use and Muscle Stretching in Peripheral Artery Disease

NCT04471792
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Creatine monohydrate, Cellulose
Drug · Dietary Supplement
Lead sponsor
Florida State University
Other
Eligibility
40 Years to 95 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jun 25, 2026, 8:07 PM EDT
Not listed Not applicable Interventional

Effect of Lower Leg Heating and Transcutaneous Electrical Nerve Stimulation on Exercise Capacity in Patients With PAD

NCT03462472
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Lower leg heating, Lower leg transcutaneous electrical nerve stimulation (TENS)
Behavioral
Lead sponsor
Salisbury University
Other
Eligibility
40 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Salisbury, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Optical Imaging Measurement of Intravascular Solution Efficacy Trial

NCT01743872
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Contrast Injection, Dextran Injection, CO2 Injection, Heparinized Normal Saline Injection
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Jun 25, 2026, 8:07 PM EDT
Recruiting Not applicable Interventional

Real-World Registry of the Rotarex(TM) Rotational Excisional Atherectomy System (XTRACT Registry)

NCT07016698
View directory record Official record
Conditions
Peripheral Arterial Disease(PAD)
Interventions
Rotarex(TM) Rotational Excisional Atherectomy System
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
22 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Lakeland, Florida • Humble, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Phase 3 Interventional

Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

NCT03006770
View directory record Official record
Conditions
Critical Limb Ischemia (CLI)
Interventions
PLX-PAD, Placebo
Biological
Lead sponsor
Pluristem Ltd.
Industry
Eligibility
45 Years to 99 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
14
States / cities
Irvine, California • Los Angeles, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Jun 25, 2026, 8:07 PM EDT
Recruiting Phase 3 Interventional

Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

NCT07318610
View directory record Official record
Conditions
Peripheral Artery Disease (PAD)
Interventions
REGN7508, REGN9933, Placebo, Rivaroxaban
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Crystal River, Florida • Amarillo, Texas • DeSoto, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jun 25, 2026, 8:07 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT04484623
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
5
States / cities
Tucson, Arizona • Fort Myers, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 25, 2026, 8:07 PM EDT
Active, not recruiting Not applicable Interventional

Telehealth to Improve Functional Status and Quality of Life in Veterans With PAD

NCT05048979
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Exercise
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 25, 2026, 8:07 PM EDT
Terminated Phase 2 Interventional Results available

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

NCT03606642
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Stent Placement
Interventions
Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
Drug · Device
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
75 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Not applicable Interventional

FORMAT Clinical Study

NCT01804088
View directory record Official record
Conditions
Symptomatic Vascular Disease of the Iliac Arteries
Interventions
Formula™ 535 Iliac Balloon-Expandable Stent
Device
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
12
States / cities
La Jolla, California • Bradenton, Florida • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Jun 25, 2026, 8:07 PM EDT
Not listed Phase 2 Interventional

Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)

NCT00146666
View directory record Official record
Conditions
Peripheral Arterial Disease, Intermittent Claudication
Interventions
Intermittent compression
Device
Lead sponsor
FlowMedic
Industry
Eligibility
40 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Jacksonville, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2009 · Synced Jun 25, 2026, 8:07 PM EDT
Terminated No phase listed Observational

The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)

NCT04197453
View directory record Official record
Conditions
ASCVD
Interventions
Not listed
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 99 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
143
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Not applicable Interventional Results available

Apollo Device for Fatigue in Systemic Sclerosis

NCT04854850
View directory record Official record
Conditions
Systemic Sclerosis, Fatigue, Raynaud Phenomenon
Interventions
Apollo
Device
Lead sponsor
Robyn T. Domsic, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Role of microRNA-210 in Regulating Oxidative Stress in Patients With PAD

NCT04089943
View directory record Official record
Conditions
Peripheral Arterial Disease, Vascular Diseases, Peripheral, Arterial Occlusive Diseases, Atherosclerosis
Interventions
Revascularization operation, Control group
Procedure · Other
Lead sponsor
University of West Florida
Other
Eligibility
30 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
Austin, Texas • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jun 25, 2026, 8:07 PM EDT
Recruiting Not applicable Interventional

Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss

NCT04228978
View directory record Official record
Conditions
Peripheral Artery Disease, Overweight or Obesity
Interventions
Weight loss, Exercise
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Chicago, Illinois • New Orleans, Louisiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jun 25, 2026, 8:07 PM EDT
Recruiting Not applicable Interventional

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

NCT07613840
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Salem, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease

NCT02719665
View directory record Official record
Conditions
Peripheral Arterial Disease, Claudication, Claudication, Intermittent, Vascular Occlusion, Vascular Calcification, Vascular Diseases, Osteoarthritis
Interventions
SPM Emulsion, Dose-modality, SPM Softgel, Dose-Modality, Placebo Softgel
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Unacylated Ghrelin to Improve FuncTioning in PAD: The GIFT Trial

NCT03358355
View directory record Official record
Conditions
Peripheral Artery Disease, PAD, Peripheral Arterial Disease
Interventions
unacelyated ghrelin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
55 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Jun 25, 2026, 8:07 PM EDT